A Phase I Study of LY3502970 in Healthy Participants

NCT06085482 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and absorption of the experimental drug LY3502970 in healthy adult participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 10 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2023-10 · est. completion 2024-01

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06085482 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.

Treatments tested

LY3502970 Drug

Administered orally
[14C]-LY3502970 Drug

Administered IV

Main thing measured	Pharmacokinetics (PK): Absolute Bioavailability of LY3502970
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06085482 ↗